AIM Rule 26
The following information is disclosed in accordance with Rule 26 of the AIM Rules for Companies.
Please see here for our Statement of Compliance with the Quoted Companies Alliance Corporate Governance Code.
Please see here for the Chairman’s Statement.
Schrödinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE
Sensyne Health plc is incorporated in England and Wales under registered number 11425451. Its main country of operation is the United Kingdom.
Please see here for a description of Business
Please see here for details on the Board and Committees.
Please see here for information on Corporate Governance.
JOINT Broker AND Nominated Advisor
Peel Hunt LLP, Moor House, 120 London Wall, London EC2Y 5ET
Liberum, 25 Ropemaker St, London EC2Y 9LY
Legal Advisers to the Company
Allen & Overy LLP, One Bishops Square, London E1 6AD
Covington & Burling LLP, 265 Strand, London WC2R 1BH
PricewaterhouseCoopers LLP, 1 Embankment Place, London WC2N 6RH
Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA
Consilium Strategic Communications, 41 Lothbury, London EC2R 7HG
The Company’s ordinary shares are admitted to trading on AIM. There are no other exchanges or trading platforms on which the Company has applied or agreed to have any of its securities (including its AIM securities) admitted or traded.
There are no restrictions on the transfer of the Company’s ordinary shares.
As of 14 July 2020, the Company’s issued share capital consists of 128,571,514 ordinary shares of 10 pence each and the following interests of shareholders in excess of 3 per cent have been notified to the Company. These shareholders were last reviewed on 3 November 2020.
A total of 82.5% of the issued share capital is not in public hands and there are no shares held in treasury.
The Company is subject to the UK City Code on Takeovers and Mergers.
Please see here for information on Regulatory News
Articles of Association
The Audit and Risk Committee's terms of reference
The Remuneration Committee's terms of reference
The Nomination Committee's terms of reference
Matters Reserved for the Board
This page was last updated on 05/11/2020